IKT

Company Overview — What Does Inhibikase Therapeutics, Inc. Do?

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Inhibikase Therapeutics, Inc. (IKT) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Milton H. Werner and employs approximately 6 people. With a market capitalization of $239M, IKT is one of the notable companies in the Healthcare sector.

Inhibikase Therapeutics, Inc. (IKT) Stock Rating — Reduce (April 2026)

As of April 2026, Inhibikase Therapeutics, Inc. receives a Reduce rating with a composite score of 24.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.IKT ranks #3,706 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Inhibikase Therapeutics, Inc. ranks #613 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

IKT Stock Price and 52-Week Range

Inhibikase Therapeutics, Inc. (IKT) currently trades at $1.70. The stock gained $0.01 (0.6%) in the most recent trading session. The 52-week high for IKT is $2.58, which means the stock is currently trading -34.1% from its annual peak. The 52-week low is $1.33, putting the stock 27.8% above its annual trough. Recent trading volume was 864K shares, suggesting relatively thin trading activity.

Is IKT Overvalued or Undervalued? — Valuation Analysis

Inhibikase Therapeutics, Inc. (IKT) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.34x, versus the sector average of 2.75x. The price-to-sales ratio is 15.64x, compared to 1.66x for the average Healthcare stock.

At current multiples, Inhibikase Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Inhibikase Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Inhibikase Therapeutics, Inc. (IKT) earns a quality factor score of 19/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -23.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -22.8% versus the sector average of -33.1%.

The operating margin is -1399.0% (sector: -66.1%). Net profit margin stands at -1299.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

IKT Debt, Balance Sheet, and Financial Health

Inhibikase Therapeutics, Inc. has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 21.70x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $38M.

IKT has a beta of 1.56, meaning it is more volatile than the broader market — a $10,000 investment in IKT would be expected to move 56.4% more than the S&P 500 on any given day. The stability factor score for Inhibikase Therapeutics, Inc. is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Inhibikase Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Inhibikase Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.49. Net income for the quarter was $-41M. Operating income came in at $-44M.

In FY 2025, Inhibikase Therapeutics, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-48M. Operating income came in at $-52M.

In Q3 2025, Inhibikase Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.13. Net income for the quarter was $-12M. Operating income came in at $-13M.

In Q2 2025, Inhibikase Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-10M. Operating income came in at $-11M.

Over the past 8 quarters, Inhibikase Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing IKT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

IKT Dividend Yield and Income Analysis

Inhibikase Therapeutics, Inc. (IKT) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

IKT Momentum and Technical Analysis Profile

Inhibikase Therapeutics, Inc. (IKT) has a momentum factor score of 36/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 13/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

IKT vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Inhibikase Therapeutics, Inc. (IKT) ranks #613 out of 838 stocks based on the Blank Capital composite score. This places IKT in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing IKT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full IKT vs S&P 500 (SPY) comparison to assess how Inhibikase Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

IKT Next Earnings Date

No upcoming earnings date has been announced for Inhibikase Therapeutics, Inc. (IKT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy IKT? — Investment Thesis Summary

The quantitative profile for Inhibikase Therapeutics, Inc. suggests caution. The quality score of 19/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. Momentum is weak at 36/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, Inhibikase Therapeutics, Inc. (IKT) earns a Reduce rating with a composite score of 24.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on IKT stock.

Related Resources for IKT Investors

Explore more research and tools: IKT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare IKT head-to-head with peers: IKT vs AZN, IKT vs SLGL, IKT vs VMD.